Antipsychotic long-acting injections: prescribing practice in the UK.

来自 NCBI

阅读量：

作者：

展开

摘要：

BACKGROUND: Data from the USA, Australia and Europe suggest that the proportion of patients with schizophrenia prescribed an antipsychotic long-acting injection (LAI) varies from around a quarter to a third. Use of LAIs has been associated with male gender and younger age. AIMS: To characterise the use of LAIs in people with schizophrenia in three clinical settings in the UK. METHOD: The study used audit data from quality improvement programmes conducted by the Prescribing Observatory for Mental Health. RESULTS: Long-acting injections were found to be prescribed for between a quarter and a third of patients, depending on the clinical setting. Flupentixol, risperidone and zuclopenthixol were most commonly prescribed and were combined with an oral antipsychotic in half of cases, frequently constituting high-dose prescribing. The use of LAIs was not consistently associated with age, gender or ethnicity. CONCLUSIONS: Antipsychotic LAIs are commonly prescribed. We did not replicate previous findings with respect to demographic variables associated with their use.

展开

关键词：

Humans Antipsychotic Agents Delayed-Action Preparations Drug Administration Schedule Schizophrenia Evidence-Based Medicine Adolescent Adult Aged Injections